ÂÜÀòÂÒÂ×

Kyle Zingaro currently serves as the Head of Gene Therapy Process Sciences at UCB, where responsibilities include defining strategies for drug substance and drug product process development, managing cGMP manufacturing processes, and leading innovation in adeno-associated viral vector manufacturing. Prior experience includes leadership roles at Thermo Fisher Scientific and Brammer Bio, where Kyle directed teams in viral vector manufacturing process transfers, technology developments, and regulatory support. Earlier positions held at Alexion Pharmaceuticals focused on upstream process development and improvements, while foundational experience includes a Ph.D. in Chemical Engineering from the University of Delaware and a B.S. in Biochemistry from Virginia Tech.